StockUS listing USINBXNASDAQHealthcareEarnings Deterioration

Inhibrx Biosciences, Inc.(INBX) Stock Analysis | Healthcare

USD --+0.00%
Reward37Moderate
Risk73High
75%Data
Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.02Bn
Reward Ratingⓘ37 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ73 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on INBX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Inhibrx Biosciences, Inc.?

, a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

AI Brief Pro

The brief on Inhibrx Biosciences, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Inhibrx Biosciences, Inc.?

, a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.02B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (37)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta4.038
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
42,000 shares
$221k
1648,440 shares
$4.9M
3-6months
0
0
6-9months
0
0
9-12months
0
0